Literature DB >> 11848536

The prognostic significance of proliferative activity, apoptosis and expression of DNA topoisomerase II alpha in multimodally-treated oesophageal squamous cell carcinoma.

M Rees1, M Stahl, B Klump, R Willers, H E Gabbert, M Sarbia.   

Abstract

The present study retrospectively examined the correlation between the outcome of patients with locally advanced oesophageal squamous cell carcinoma (cT3-4 cN0-1 cM0) after multimodal treatment (radiochemotherapy +/- surgical resection) and the parameters proliferative activity, apoptotic index and expression of the nuclear enzyme topoisomerase II alpha (topo II alpha) in pre-therapeutic tumour biopsies. Fifty-eight patients who took part in a prospective multicentred trial received radiochemotherapy, optionally followed by surgery. Pre-therapeutic biopsies were immunohistochemically investigated for the extent of proliferation (MIB-I index) and expression of the topo II alpha-enzyme. The apoptotic index was determined by the TUNEL-assay. The three parameters were correlated with tumour response to polychemotherapy and with overall survival. Topo II alpha expression was found in all samples with different percentages of positive cells. The proliferation indices ranged between 9% and 97% (median: 43%) while the apoptotic indices ranged between 0.2% and 2.8% (median: 0.5%). Strong expression of topo II alpha (>50% positive tumour cells) was positively-correlated with response to polychemotherapy (p=0.016) whereas proliferative activity or apoptotic index showed no impact. None of the three parameters under investigation was predictive of overall survival. Pre-therapeutic determination of topo II alpha expression may predict chemosensitivity of oesophageal squamous cell carcinomas. However, determination of proliferative activity and apoptotic index has no predictive value.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11848536

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Examining Nek2 as a better proliferation marker in non-small cell lung cancer prognosis.

Authors:  Xinwen Zhong; Xiaojiao Guan; Qianze Dong; Shize Yang; Wenke Liu; Lin Zhang
Journal:  Tumour Biol       Date:  2014-04-25

2.  Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas.

Authors:  Xiao-Ling Xu; Wei-Hui Zheng; Zhi-Xuan Fu; Zhu-Peng Li; Hua-Xia Xie; Xian-Xing Li; Lie-Hao Jiang; Yin Wang; Shuang-Mei Zhu; Wei-Min Mao
Journal:  Med Oncol       Date:  2014-11-29       Impact factor: 3.064

Review 3.  Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.

Authors:  Masahide Ikeguchi; Yosuke Arai; Yoshihiko Maeta; Keigo Ashida; Kuniyuki Katano; Toshiro Wakatsuki
Journal:  Surg Today       Date:  2011-08-26       Impact factor: 2.549

4.  Aberrant expression of NEK2 and its clinical significance in non-small cell lung cancer.

Authors:  Xinwen Zhong; Xiaojiao Guan; Wenke Liu; Lin Zhang
Journal:  Oncol Lett       Date:  2014-07-30       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.